In short
In 2021, Sciensano established the BelCoVac consortium uniting the expertise of Belgian immunological experts and clinicians across different universities and research laboratories, the Belgian Pandemic Preparedness (BelPaPrep) Labs. The consortium allows for the generation of uniform and comparable data throughout the different studies it encompasses. All studies focus on monitoring the immune response in different population groups after vaccination with different COVID-19 vaccines.
Project description
The BelCoVac consortium consists of Belgian clinicians and immunology experts from universities and research laboratories. Together, they conduct clinical studies to investigate the immune response in (vulnerable) population groups after vaccination with different COVID-19 vaccines. The consortium is coordinated by the Platform interventional studies of Sciensano, headed by Maria Goossens.
The studies are as followed:
- Influence of prior infection with SARS-CoV-2 on occurrence of influenza-like illness or acute respiratory infection (PICOV) – Maria Goossens (Sciensano)
- Immune response to mRNA vaccine doses in SARS-CoV-2 infection naïve nursing home residents and staff (PICOV-VAC) – Maria Goossens (Sciensano)
- Safety and immunogenicity of demi-dose of two Covid-19 mRNA vaccines in healthy population (REDU-VAC) – Maria Goossens (Sciensano)
- SARS-CoV-2 vaccination in kidney transplant recipients and in hemodialysis patients: a phase IV study of the immunogenicity and its determinants (Nephro-Vac) – Alain Le Moine (ULB)
- Vaccination against Covid-19 in cancer patients under active treatment (Onco-Vac) –Marc Peeters (UZA)
- Impact of the immune system on response to Covid-19 vaccine in allogeneic stem cell recipients (Cov-Allo) – Frédéric Baron (CHU Liège)
- Vaccination against Covid-19 in pregnant and lactating women in Belgium (PREGCOVAC) – Kirsten Maertens (UA)
- COVID-19 vaccination in breastfeeding mothers (COVALAC) – Eline Tommelein (VUB)
- COVID 19 and lung transplantation: study of clinical characteristics and humoral and cellular response to SARS-CoV-2 infection and anti-SARS-CoV-2 vaccination in lung transplant patients (LUNG-VAC) – Isabelle Etienne (ULB)
- Immunogenicity after COVID-19 vaccines in Adapted Schedules in healthy adults (IMCOVAS) – Katie Steenackers/Nikita Hanning (UA) (funded by KCE)
- Longitudinal follow-up of SARS-CoV-2 immunity in immunocompromised populations in Belgium (COVICO) – Maria Goossens (Sciensano)
Sciensano's project investigator(s):
Service(s) working on this project
Partners
